Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on TALANX AG. We currently have 7 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
Preliminary net profit clearly above our expectations
07 Feb 17
Talanx said that, on the basis of consolidated, preliminary numbers, it has achieved a group net income of slightly above €900m for FY2016 and at least 23% above FY2015’s net profit. On the one hand, this results from lower than expected large losses in the group and, on the other, special tax effects have also contributed to the improvement of the result. The proposed dividend per share is increased from €1.30 for FY2015 to €1.35 for FY2016. For 2017, Talanx raises the outlook for group net income to around €800m from previously at least €750m. Talanx is due to release its final financial results as well as its annual report on 20 March 2017.
Good Q3 results and new but unambitious FY2017 target
15 Nov 16
Net attributable profit increased by 32% to €234m for Q3 16 compared to Q3 15. Net premiums earned declined by 3% to €6.3bn for Q3 16 compared to the same period last year. The net investment result was up by 7% to €1.02bn for Q3 16. RoI was 3.5% for 9M 16 compared to 3.7% for 9M 15. Insurance claims decreased by 5% to €5.2bn in Q3 16 compared to Q3 15. The group net combined ratio of the non-life business was 96.4% for Q3 16 compared to 98.0% for Q3 15. Pre-tax profit rose by 20% to €548m for Q3 16. Equity capital attributable to common shares increased by 9% to €9.0bn at the end of September 2016 compared to the end of 2015. Talanx slightly raised its outlook for group net income for 2016 from “approximately” to “at least” €750m. Additionally, Talanx released a net profit target for FY2017 for the first time. It is looking to generate group net attributable profit of again at least €750m for FY2017.
Q2 figures in line with expectations and guidance
12 Aug 16
Net attributable profit tripled from €60m for Q2 15 to €179m for Q2 16 due to a goodwill impairment of €155m on the German life business in Q2 15. Net premiums earned were up by 2.5% to €6.5bn for Q2 16 compared to Q2 15. The net investment result declined by 10% to €940m for Q2 16. Insurance claims were up by 1% to €5.3bn in Q2 16. The group’s net combined ratio of the non-life business increased from 96.2% for Q2 15 to 97.3% for Q2 16. Pre-tax profit was up by 39% to €455m for Q2 16 compared to the same period last year. Equity capital attributable to common shares rose by 4.5% to €8.65bn at the end of June 2016 compared to the end of 2015 due to higher unrealised gains. RoE was 8.4% for Q2 16 versus 2.8% for Q2 15. Talanx confirmed its net attributable profit target for FY2016 of €750m. The Solvency II stood at 171% at the end of 2015.
Solid start to 2016
13 May 16
Net attributable profit decreased by 12% to €222m for Q1 16 compared to Q1 15 which benefited from a special effect of €19m net. Net premiums earned were down by 1.5% to €6.3bn for Q1 16 compared to the same period last year. The net investment result rose by 3% to €1.02bn for Q1 16. RoI was around 3.7% for Q1 16 compared to 3.6% in Q1 15. Insurance claims declined by 2.2% to €5.2bn in Q1 16 compared to Q1 15. Group net combined ratio of the non-life business was 96.3% for Q1 16 compared to 96.5% for Q1 15. Pre-tax profit decreased by 10% to €536m for Q1 16. RoE after tax was 10.6% for Q1 16 compared to 12.0% for Q1 15. Equity capital attributable to common shares increased by 3% to €8.5bn at the end of March 2016 compared to the end of 2015. Talanx confirmed its net attributable profit target for FY2016 of €750m. The Solvency II stood at 171% at the end of 2015.
Good FY2015 figures and a slightly increased dividend proposal
21 Mar 16
Net attributable profit decreased by 5% to €734m for FY2015 compared to FY2014. Net premiums earned rose by 9% to €25.9bn for 2015 compared to 2014 and were up by around 4.5% at constant currency. The net investment result was down by 5% to €3.9bn for 2015. RoI was around 3.6% for 2015 compared to 4.1% in 2014 which benefited from the sale of a Swiss Life stake. Insurance claims were up by 7% to €21.44bn in 2015 compared to 2014. Group net combined ratio of the non-life business declined from 97.9% for 2014 to 96.0% for 2015. Operating profit before goodwill impairments increased by 24% to €2.34bn for FY2015. A goodwill impairment of €155m on the German life business (Q2 15) burdened the 2015 result. Pre-tax profit rose by 18% to €2.0bn for 2015. The tax ratio was 28% for FY2015 compared to 18% for 2014 which benefited from a tax-free disposal gain and the release of provisions for deferred taxes. Equity capital attributable to common shares increased by 3.6% to €8.3bn at the end of 2015 compared to the end of 2014. RoE was 9.0% for FY2015 compared to 10.2% for FY2014. The dividend proposal increased from €1.25 per share for FY2014 to €1.30 per share for FY2015. Talanx increased the net profit target from more than €700m to around €750m for FY2016. The capital resources of the Talanx Group in accordance with Solvency I stood at 219% at the end of 2015 compared to 228% at the end of 2014.
Solid Q3 figures and new disappointing FY2016 target
12 Nov 15
Net attributable profit increased by 19% to €177m for Q3 15 compared to Q3 14. Net premiums earned rose by 11.5% to €6.5bn for Q3 15 compared to the same period last year. The net investment result was down by 9% to €952m for Q3 15. RoI was around 3.3% for Q3 15 compared to 4.0% in Q3 14. Insurance claims were up by 9.5% to €5.4bn in Q3 15 compared to Q3 14. Group net combined ratio of the non-life business was 98.0% for Q3 15 compared to 100.0% for Q3 14. Pre-tax profit rose by 15% to €455m for Q3 15. Equity capital attributable to common shares increased by 1% to €8.1bn at the end of September 2015 compared to the end of 2014. Talanx released a net profit target for FY2016 for the first time. It is looking to generate group net attributable profit of more than €700m for FY2016. The capital resources of the Talanx Group in accordance with Solvency I stood at 227.5% compared to 228.2% at the end of 2014.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
28 Mar 17
ClearStar* (CLSU): Building a background for growth (CORP) | Sound Energy (SOU): TE-8 results (HOLD) | LiDCO* (LID): 2017 should be a transformative year (CORP) | Proteome Sciences* (PRM): FY 2016 in line. Moving towards breakeven (CORP) | Fulcrum (FCRM): Significant market potential, rising margins and a strong balance sheet (BUY) | Mortgage Advice Bureau (MAB1): Strong and growing intellectual property (BUY) | 7digital* (7DIG): Open offer result (CORP)
Small Cap Breakfast
28 Mar 17
Path Investments—Publication of prospectus from the Energy Investment Company. Raising £1.4m. Admission due on or around 30 March | Franchise Brands—Schedule 1 detailing £28m reverse takeover of Metro Rod. Admission expected 11 April | Alpha FX Group— Schedule 1 from the foreign exchange provider focused on managing exchange rate risk for UK corporates that trade internationally. Fundraise TBC. Admission expected 7 April. | K3 | Capital Group—Schedule 1 from the Group of business and company sales specialists across business transfer, business brokerage and corporate finance. Admission date and fundraise details TBC. | Integumen— Schedule 1 from the personal health company developing and commercialising technology and products for the human integumentary system. Raising £2.16m at 5p. Expected market cap £8.16m. Admission expected 5 April. Tufton | Oceanic Assets– Offer extended to 9 May to enable investors to complete further due diligence.